About: Zalutumumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer.

Property	Value
dbo:abstract	Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. (en) Залутумумаб (запропонована торгова назва HuMax-EGFR ) - це повне моноклональне людське антитіло IgG1 (mAb), спрямоване проти рецептору епідермального фактора росту (EGFR). Розробник - компанія Genmab (Утрехт, Нідерланди). Зокрема, залутумумаб був призначений для лікування плоскоклітинного раку голови та шиї (SCCHN). (uk)
dbo:casNumber	667901-13-5
dbo:fdaUniiCode	DA709Q5020
dbo:kegg	D10031
dbo:wikiPageID	9701109 (xsd:integer)
dbo:wikiPageLength	7416 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1093965708 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Cancer dbr:Epidermal_growth_factor dbr:Epidermal_growth_factor_receptor dbr:Extracellular-signal-regulated_kinase dbr:FDA_Fast_Track_Development_Program dbr:Natural_killer_cell dbr:Antibody-dependent_cellular_cytotoxicity dbc:Abandoned_drugs dbr:Competitive_antagonist dbr:Genmab dbr:Monoclonal_antibody dbr:Apoptosis dbr:Lipophilic dbr:Statistical_significance dbr:P21_activated_kinase dbr:Progression-free_survival dbr:U.S._Food_and_Drug_Administration dbr:Grb2 dbr:Angiogenesis dbr:Cell_adhesion dbr:Cell_cycle dbr:Cell_migration dbr:Fragment_crystallizable_region dbr:Receptor_tyrosine_kinase dbr:Guanosine_diphosphate dbr:Guanosine_triphosphate dbr:Inverse_agonist dbc:Monoclonal_antibodies_for_tumors dbr:Chemotherapy dbr:Binding_domain dbr:CD16 dbr:Lymphocyte dbr:Phosphorylation dbr:TGF_alpha dbr:MAPK/ERK_kinase dbr:Protein_phosphatase_2A dbr:Utrecht_(city) dbr:SCCHN dbr:Metastasize dbr:Squamous_cell_carcinoma dbr:Protein_dimerization dbr:Fragment_antigen_binding dbr:Raf-1 dbr:Ras_(protein) dbr:Overall_survival dbr:Elk-1
dbp:atcPrefix	none (en)
dbp:c	6512 (xsd:integer)
dbp:casNumber	667901 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	10074 (xsd:integer)
dbp:kegg	D10031 (en)
dbp:mabType	mab (en)
dbp:n	1734 (xsd:integer)
dbp:o	2032 (xsd:integer)
dbp:s	46 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:Epidermal_growth_factor_receptor
dbp:type	mab (en)
dbp:unii	DA709Q5020 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	470635509 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Growth_factor_receptor_modulators dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Abandoned_drugs dbc:Monoclonal_antibodies_for_tumors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodiesForTumors yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct
rdfs:comment	Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. (en) Залутумумаб (запропонована торгова назва HuMax-EGFR ) - це повне моноклональне людське антитіло IgG1 (mAb), спрямоване проти рецептору епідермального фактора росту (EGFR). Розробник - компанія Genmab (Утрехт, Нідерланди). Зокрема, залутумумаб був призначений для лікування плоскоклітинного раку голови та шиї (SCCHN). (uk)
rdfs:label	Zalutumumab (en) Залутумумаб (uk)
owl:sameAs	freebase:Zalutumumab yago-res:Zalutumumab wikidata:Zalutumumab dbpedia-uk:Zalutumumab https://global.dbpedia.org/id/4xPsH
prov:wasDerivedFrom	wikipedia-en:Zalutumumab?oldid=1093965708&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Zalutumumab
is dbo:wikiPageRedirects of	dbr:HuMax-EGFr
is dbo:wikiPageWikiLink of	dbr:Epidermal_growth_factor_receptor dbr:HuMax-EGFr dbr:HuMax dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Hf–Hz dbr:List_of_drugs:_Z
is foaf:primaryTopic of	wikipedia-en:Zalutumumab